Search
Adenosine phosphate
go.drugbank.com/drugs/DB00131ApprovedInvestigationalNutraceuticalWithdrawnAdenosine phosphate was withdrawn by the FDA since it was considered neither safe nor effective for its intended uses as a vasodilator and an anti-inflammatory.[L43937] … Adenosine phosphate, or adenylic acid, is an adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.
Synonyms: Ado5'P, Adenosine-5'PGlasdegib
go.drugbank.com/drugs/DB11978ApprovedInvestigational[A258493] Aberrant of Hh signaling is one of the main pathophysiologies of AML, with observed overexpression or constitutive activation of SMO. … [A40310] Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML).
Categories: Smoothened Receptor Antagonists, Cytochrome P-450 SubstratesEtoperidone
go.drugbank.com/drugs/DB09194ApprovedWithdrawnEtoperidone is an atypical antidepressant introduced in Europe in 1977. … It is a phenylpiperazine-substituted triazole derivative with a composition that classifies it as an analog of tradozone and presents a similar pharmacological profile.
Categories: Serotonin Receptor Antagonists, Serotonin 5-HT2 Receptor AntagonistsEstrone
go.drugbank.com/drugs/DB00655ApprovedEstrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase. … Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol.
Categories: P-glycoprotein inducers, Cytochrome P-450 SubstratesAVI-4557
go.drugbank.com/drugs/DB05447ExperimentalAVI-4557 is an oral antisense compound that selectively inhibits the metabolic enzyme cytochrome P450 3A4 (CYP), a liver enzyme responsible for the metabolism or breakdown of approximately half of currently … Studies indicate that AVI-4557 can successfully reduce the rate of metabolism for certain drugs, therefore allowing greater and longer availability of the drug in the patient's system through a decrease
Zidesamtinib
go.drugbank.com/drugs/DB21623ApprovedInvestigational[L63808,L63933] Zidesamtinib is selective for ROS1, retains activity in cells carrying the common resistance mutations, and showed antitumor activity in an intracranial model, positioning it for use after … another ROS1 inhibitor has failed rather than as an alternative first choice.
Rofecoxib
go.drugbank.com/drugs/DB00533ApprovedWithdrawnRofecoxib has a half-life of 17 hours and its mean oral bioavailability at therapeutically recommended doses of 125, 25, and 50 mg is approximately 93%. … Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersAlbiglutide
go.drugbank.com/drugs/DB09043ApprovedInvestigationalWithdrawnAlbiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant ...
Sulfapyridine
go.drugbank.com/drugs/DB00891ApprovedWithdrawnAntibacterial, potentially toxic, and previously used to treat certain skin diseases. No longer prescribed.
Synonyms: 2-(p-Aminobenzenesulphonamido)pyridineCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseRexin G
go.drugbank.com/drugs/DB16450InvestigationalIt is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for preventing SARSCOV-2 viral entry.
Categories: Experimental Unapproved Treatments for COVID-19